Impact of Subsequent Biopsies on Comprehensive Health Related Quality of Life in Patients With and Without Prostate Cancer.

The aim of this study was to identify the effects of subsequent prostate needle biopsies after baseline biopsy on health related quality of life over time, comparing men with and without prostate cancer and men receiving or not receiving follow up prostate needle biopsy.

Patients enrolled in the Center for Prostate Disease Research Multicenter National Database between 2007 and 2015, with low and favorable intermediate risk prostate cancer on active surveillance and undergoing prostate needle biopsy for suspicion of prostate cancer were included for analysis. Patients completed the Expanded Prostate Cancer Index Composite and the RAND 36-Item Short Form Health Survey after baseline biopsy and at regular follow-up intervals. Mean health related quality of life was compared over time between patients who did and did not undergo subsequent prostate needle biopsies following baseline.

637 patients were included; 129 (20.3%) with prostate cancer on active surveillance, 508 (79.7%) in the non-cancer group. Mean follow up was 34.7 (SD ± 16.9) and 31.6 (SD ± 14.6) months, respectively. 54 (60.7%) of prostate cancer patients had subsequent prostate needle biopsies, compared with 114 (27.1%) of non-cancer patients. No significant impact on health related quality of life was observed in men undergoing subsequent prostate needle biopsies over a five year period.ConclusionSubsequent prostate needle biopsy is required in most active surveillance protocols and in those with persistent suspicion of prostate cancer. Our analysis shows that subsequent prostate needle biopsies do not significantly impact health related quality of life.

The Journal of urology. 2019 Jan 25 [Epub ahead of print]

John F Burns, Lauren M Hurwitz, Katherine E Levie, Fernando Caumont, Timothy C Brand, Inger L Rosner, Sean Stroup, John E Musser, Jennifer Cullen, Christopher R Porter

Virginia Mason Medical Center, Seattle, WA., Center for Prostate Disease Research, Department of Defense, Rockville, MD.